Reporte zur Charge GH9703 FMMJ

Symptomtext

COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient. A 59-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2021 as dose 3 (booster), single (Lot number: 301308A), in right arm, on 01Jul2022 as dose 4 (booster), single (Lot number: FN2908), in right arm and on 29Nov2022 at 11:30 as dose 5 (booster), single (Lot number: GH9703 FMMJ) at the age of 58 years, in right arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 31Dec2020 as dose 1, single (Lot number: EL0142), in right arm and on 22Jan2021 as dose 2, single (Lot number: EL3249), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "known allergies: PCN" (unspecified if ongoing), notes: Known allergies: PCN; "Thyroid disorder" (unspecified if ongoing); "Nerve Damage" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Sinus disorder" (unspecified if ongoing). Concomitant medication(s) included: ALBUTEROL [SALBUTAMOL SULFATE] taken for asthma; GABAPENTIN taken for nerve injury; MUCINEX taken for sinus disorder; PROTONIX [OMEPRAZOLE] taken for gastrooesophageal reflux disease; SYNTHROID taken for thyroid disorder. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jan2023, outcome "recovering" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19 which included Paxlovid taken from 17Jan2023 to 22Jan2023.